Tempus AI, Inc. (NASDAQ:TEM) is Revolution Growth Management Company Inc.’s Largest Position

Revolution Growth Management Company Inc. lowered its stake in Tempus AI, Inc. (NASDAQ:TEM) by 5.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,467,565 shares of the company’s stock after selling 193,383 shares during the period. Tempus AI makes up approximately 100.0% of Revolution Growth Management Company Inc.’s holdings, making the stock its largest holding. Revolution Growth Management Company Inc. owned about 2.20% of Tempus AI worth $117,065,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Kovitz Investment Group Partners LLC bought a new position in shares of Tempus AI during the third quarter valued at approximately $1,367,000. Sumitomo Mitsui Trust Group Inc. increased its position in Tempus AI by 1,591.2% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,217,699 shares of the company’s stock valued at $68,922,000 after purchasing an additional 1,145,698 shares during the period. China Universal Asset Management Co. Ltd. bought a new position in Tempus AI in the 4th quarter worth $1,091,000. Captrust Financial Advisors purchased a new stake in shares of Tempus AI in the 3rd quarter worth about $2,726,000. Finally, Sigma Planning Corp bought a new stake in shares of Tempus AI during the 3rd quarter valued at about $1,323,000. Institutional investors own 24.22% of the company’s stock.

Insiders Place Their Bets

In related news, Director David R. Epstein sold 620 shares of the firm’s stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $41.81, for a total value of $25,922.20. Following the transaction, the director now directly owns 27,894 shares of the company’s stock, valued at approximately $1,166,248.14. This trade represents a 2.17 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Bradley A. Keywell sold 265,000 shares of the business’s stock in a transaction dated Friday, January 17th. The shares were sold at an average price of $35.10, for a total value of $9,301,500.00. Following the sale, the insider now directly owns 15,218,365 shares of the company’s stock, valued at $534,164,611.50. This represents a 1.71 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 2,037,702 shares of company stock valued at $89,449,651.

Tempus AI Stock Up 0.3 %

TEM stock opened at $57.39 on Monday. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69. Tempus AI, Inc. has a 1 year low of $22.89 and a 1 year high of $79.49. The stock’s fifty day moving average price is $44.18 and its 200-day moving average price is $48.29.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on TEM. Stifel Nicolaus lowered Tempus AI from a “buy” rating to a “hold” rating and increased their target price for the stock from $45.00 to $65.00 in a research report on Monday, November 11th. Needham & Company LLC reiterated a “buy” rating and issued a $56.00 price objective on shares of Tempus AI in a report on Tuesday, January 14th. Bank of America boosted their target price on shares of Tempus AI from $52.00 to $54.00 and gave the company a “neutral” rating in a report on Friday, December 13th. Wolfe Research started coverage on shares of Tempus AI in a research report on Friday, December 13th. They issued an “outperform” rating and a $60.00 target price on the stock. Finally, Piper Sandler reissued a “neutral” rating and set a $70.00 price target (up from $40.00) on shares of Tempus AI in a research report on Tuesday, November 12th. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $56.36.

Tempus AI Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.